The current status of cancer biomarker research using tumour-associated antigens for minimal invasive and early cancer diagnostics

Coronell, Johana A. Luna; Syed, Parvez; Sergelen, Khulan; Gyurján, István; Weinhäusel, Andreas

doi:10.1016/j.jprot.2012.07.022

Cited by 42 publications

(41 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence for a specific humoral response against a number of intracellular and surface tumoral antigens is now well-established in patients with breast cancer (9).…”

Section: Introductionmentioning

confidence: 99%

A Multiparametric Serum Marker Panel as a Complementary Test to Mammography for the Diagnosis of Node-Negative Early-Stage Breast Cancer and DCIS in Young Women

Lacombe

Mangé

Bougnoux

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: The sensitivity of mammography for the detection of small lesions, including node-negative early-stage (T1N0) primary breast cancer (PBC) and ductal carcinoma in situ (DCIS), is significantly decreased in young patients. From a clinical standpoint, an inconclusive mammogram reflects the inability of clinicians to confidently decide whether patients should be referred for biopsy or for follow-up with repeat imaging.Methods: Specific ELISAs were developed for a panel of 13 well-recognized breast autoantigens (HSP60, FKBP52, PRDX2, PPIA, MUC1, GAL3, PAK2, P53, CCNB1, PHB2, RACK1, RUVBL1, and HER2). Circulating autoantibody levels were measured in a cohort of 396 serum samples from histologically confirmed DCIS (n ¼ 87) or T1N0 PBC (n ¼ 153) and healthy controls (n ¼ 156).Results: Individually, antibodies against CCNB1, FKBP52, GAL3, PAK2, PRDX2, PPIA, P53, and MUC1 demonstrated discriminatory power between breast cancer and healthy control groups. At 90% sensitivity, the overall combined specificity of the autoantibody serum screening test was 42%. Adjustment for higher sensitivities of 95% and 99% resulted in 30% and 21% specificities, respectively (33% and 18% in T1N0 PBC and 28% and 21% in DCIS). Finally, in patients with node-negative early-stage breast cancer younger than 50 years, the autoantibody assay exhibited 59% specificity with a fixed sensitivity at 90%.Conclusions: Our autoantibody panel allows accurate detection of early breast cancer and DCIS, notably in younger patients.Impact: Clinical assessment of this autoantibody panel displays a potential to facilitate clinical management of early-stage breast cancer detection in cases of inconclusive mammogram. Cancer Epidemiol Biomarkers Prev; 23(9); 1834-42. Ó2014 AACR.

show abstract

“…Evidence for a specific humoral response against a number of intracellular and surface tumoral antigens is now well-established in patients with breast cancer (9).…”

Section: Introductionmentioning

confidence: 99%

A Multiparametric Serum Marker Panel as a Complementary Test to Mammography for the Diagnosis of Node-Negative Early-Stage Breast Cancer and DCIS in Young Women

Lacombe

Mangé

Bougnoux

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Early detection of cancer continues to be a formidable challenge to the scientific community and search for a suitable biomarker for use in mass screening of population is of utmost importance in our fight against cancer (Khan et al, 2012;Luna et al, 2012;van der Bilt et al 2012;Bao et al, 2013;Hensing and Salgia, 2013;Suradej et al, 2013;Wang et al, 2013;Behrens et al, 2014;Sigari et al, 2014). Constant efforts are being made worldwide to find an effective and reliable biomarker and a convenient assay for early detection of cancers, especially in its initiation stage, which is when a cell gets committed to transformation.…”

Section: Discussionmentioning

confidence: 99%

Dimethylnitrosamine-Induced Reduction in the Level of Poly-ADP-Ribosylation of Histone Proteins of Blood Lymphocytes - a Sensitive and Reliable Biomarker for Early Detection of Cancer

Kma

Sharan²

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Poly-ADP-ribosylation (PAR) is a post-translational modification of mainly chromosomal proteins. It is known to be strongly involved in several molecular events, including nucleosome-remodelling and carcinogenesis. In this investigation, it was attempted to evaluate PAR level as a reliable biomarker for early detection of cancer in blood lymphocyte histones. PAR of isolated histone proteins was monitored in normal and dimethylnitrosamine (DMN)-exposed mice tissues using a novel ELISA-based immuno-probe assay developed in our laboratory. An inverse relationship was found between the level of PAR and period of DMN exposure in various histone proteins of blood lymphocytes and spleen cells. With the increase in the DMN exposure period, there was reduction in the PAR level of individual histones in both cases. It was also observed that the decrease in the level of PAR of histones resulted in progressive relaxation of genomic DNA, perhaps triggering activation of genes that are involved in initiation of transformation. The observed effect of carcinogen on the PAR of blood lymphocyte histones provided us with a handy tool for monitoring biochemical or physiological status of individuals exposed to carcinogens without obtaining biopsies of cancerous tissues, which involves several medical and ethical issues. Obtaining blood from any patient and separating blood lymphocytes are routine medical practices involving virtually no medical intervention, post-procedure medical care or trauma to a patient. Moreover, the immuno-probe assay is very simple, sensitive, reliable and cost-effective. Therefore, combined with the ease of preparation of blood lymphocytes and the simplicity of the technique, immuno-probe assay of PAR has the potential to be applied for mass screening of cancer. It appears to be a promising step in the ultimate goal of making cancer detection simple, sensitive and reliable in the near future.

show abstract

“…Recent development in microelectronics has led to the birth of biosensors for a large range of biological recognized elements (virus, bacteria, pesticides, etc…). This will ensure an early diagnosis and personalized treatment, a sensitive and selective detection of disease biomarkers [1][2][3][4][5][6]. CVD are the leading cause of death in the world due to ischemic complications including heart disease and stroke [7,8].…”

Section: Introductionmentioning

confidence: 99%

A disposable electrochemical sensor based on protein G for High-Density Lipoprotein (HDL) detection

Chammem

Hafaid

Bohli

et al. 2015

Talanta

View full text Add to dashboard Cite

The current status of cancer biomarker research using tumour-associated antigens for minimal invasive and early cancer diagnostics

Cited by 42 publications

References 130 publications

A Multiparametric Serum Marker Panel as a Complementary Test to Mammography for the Diagnosis of Node-Negative Early-Stage Breast Cancer and DCIS in Young Women

A Multiparametric Serum Marker Panel as a Complementary Test to Mammography for the Diagnosis of Node-Negative Early-Stage Breast Cancer and DCIS in Young Women

Dimethylnitrosamine-Induced Reduction in the Level of Poly-ADP-Ribosylation of Histone Proteins of Blood Lymphocytes - a Sensitive and Reliable Biomarker for Early Detection of Cancer

A disposable electrochemical sensor based on protein G for High-Density Lipoprotein (HDL) detection

Contact Info

Product

Resources

About